No Data
No Data
Zhixiang Jintai (688443.SH): At the end of the term, Jiang Ren, the actual controller, increased the company's shares by about 31.22,200 yuan
Gelonghui, May 17, 丨 Zhixiang Jintai (688443.SH) announced that as of May 16, 2024, the actual controller, Mr. Jiang Rensheng, had increased his holdings of the company's 875,582 shares through centralized bidding through the Shanghai Stock Exchange trading system, accounting for about 0.24% of the company's total issued share capital. The total increase amount amount of about RMB 31.22,200 million has been reached, reaching the lower limit of the increase range of RMB 30 million. The period of this increase plan has expired and the implementation of the increase in holdings has been completed.
Is Chongqing Genrix Biopharmaceutical (SHSE:688443) Using Too Much Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will
Zhixiang Jintai (688443.SH) reported first-quarter results with a net loss of 164 million yuan
Zhixiang Jintai (688443.SH) released its report for the first quarter of 2024, with revenue of 6,330.27...
Guoxin Securities: The pharmaceutical industry is entering an upward inflection point in the medium to long term, and focus on high growth targets in the quarterly report in the short term
The pharmaceutical industry currently has low growth, low profitability, undervaluation, and low transaction attention, and is entering a major layout range at an upward inflection point in the medium to long term.
Private Equity Firms in Chongqing Genrix Biopharmaceutical Co., Ltd. (SHSE:688443) Are Its Biggest Bettors, and Their Bets Paid off as Stock Gained 15% Last Week
Key Insights The considerable ownership by private equity firms in Chongqing Genrix Biopharmaceutical indicates that they collectively have a greater say in management and business strategy The larg
Guoxin Securities: Focus on the immediate needs of medical care, focus on the high growth targets of the first quarter report
The pharmaceutical industry currently has low growth, low profitability, undervaluation, and low transaction attention, and is entering a major layout range at an upward inflection point in the medium to long term.
No Data